Jasper Therapeutics, Inc. - Voting Common Stock, par value $0.0001 per share (JSPR)

CUSIP: 471871202

Q3 2026 13F Holders as of 30 Sep 2026

Holder snapshot 5 signals
Share change
-50
SEC-reported price per share
$0.57
Number of holders
1
Value change
-$29
Number of sells
1
Security identity Names, identifiers, and filing context for this profile. 1 source field
Shares outstanding
33,973,202

Security key

471871202

Report period

Q3 2026

Institutions

1

Top holders

1

Ownership snapshot

Top reported holders of JSPR - Jasper Therapeutics, Inc. - Voting Common Stock, par value $0.0001 per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
Velan Capital Investment ...
Disclosed value leader
Velan Capital Investment ...
Comparable rows
11/15
Latest evidence
30 Jun 2026
3/4/5 13D/G 13F Lead comparable stake: 9.9% 4 rows are not safely comparable across share classes. 13D/G row: Velan Capital Investment Management LP Showing 1-6 of 15 holder rows.

Quick read

Velan Capital Investment Management LP leads the comparable SEC ownership view at 9.9%.

11 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens Velan Capital Investment Management LP's linked filing trail.
Comparable ownership Top 5
Velan Capital Investment Manageme... 9.9%
T. Rowe Price Investment Manageme... 7.1%
ACORN BIOVENTURES, L.P. 5.3%
MORGAN STANLEY 4.8%
KINGDON CAPITAL MANAGEMENT, L.L.C. 4.7%

Ownership % is shown only when SEC disclosures are safely comparable across share classes.

Detailed SEC evidence table Showing 1-6 of 15 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
Velan Capital Investment Management LP
3/4/5 13D/G 13F
10%+ Owner · Company
9.9%
Reported 13D/G · 17 Aug 2026
$18,568,073
1,433,828 shares
— 08 Feb 2024
T. Rowe Price Investment Management, Inc.
13D/G
7.1%
Reported 13D/G · 30 Sep 2025
$4,897,117
2,057,612 shares
$0 30 Sep 2025
ACORN BIOVENTURES, L.P.
13D/G
Anders Hove
5.3%
Reported 13D/G · 23 Jan 2026
$2,660,821
1,486,492 shares
-$537,000 23 Jan 2026
MORGAN STANLEY
13D/G 13F
Company
4.8%
Reported 13D/G · 31 Mar 2026
$1,226,746
1,333,420 shares
-$585,456 31 Mar 2026
KINGDON CAPITAL MANAGEMENT, L.L.C.
13D/G 13F
Company
4.7%
Reported 13D/G · 30 Sep 2025
$3,153,131
1,324,845 shares
+$1,332,431 30 Sep 2025
Carlyle Group Inc.
3/4/5 13D/G 13F
Former 10% Owner · The Carlyle Group Inc. · Company
3.8%
Reported 13D/G · 18 Feb 2026
$13,807,148
1,066,189 shares
— 08 Feb 2024
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q3 2026

Investor-level positions for this CUSIP, loaded as an interactive table.

Institutions
1
Shares
14
Rows available
1
Investor Option Weight % Change % SEC-reported value * Price Shares Share Change Activity Report Period

* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Compare Q3 2026 vs Q2 2026 Across Filers

Q2 2026 holders
43
Q3 2026 holders
1
Holder diff
-42
Investor Q2 2026 Shares Q3 2026 Shares Share Diff Share Chg % Q2 2026 value Q3 2026 value Value change Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .